Emerging concepts and treatment in neuropathic pain kongkiat kulkantrakorn

Neurology Asia

Volumn 17, Issue 4, 2012, Pages 265-271

  Kulkantrakorn, Kongkiat ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CANNABINOID; CANNABINOID 2 RECEPTOR AGONIST; CAPSAICIN; CELECOXIB; CYCLIC NUCLEOTIDE GATED CHANNEL; DEXTROMETHORPHAN; DRONABINOL; DULOXETINE; EXCITATORY AMINO ACID TRANSPORTER 1; G PROTEIN COUPLED RECEPTOR; GABAPENTIN; HARKOSERIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETAMINE; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NABILONE; PLACEBO; PREGABALIN; QUINIDINE; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; STRESS ACTIVATED PROTEIN KINASE; TAPENTADOL; TETRAHYDROCANNABINOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VESICULAR GLUTAMATE TRANSPORTER 1;

ALLODYNIA; ASTROCYTE; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; CYTOKINE PRODUCTION; DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ERYTHROMELALGIA; FIBROMYALGIA; FOCAL EPILEPSY; HUMAN; HYPERALGESIA; LOW BACK PAIN; MICROGLIA; MITOCHONDRIAL PERMEABILITY; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL PAIN; NERVE EXCITABILITY; NERVE INJURY; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN RECEPTOR; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROTEIN PHOSPHORYLATION; RADICULOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SENSORY STIMULATION; SINGLE DRUG DOSE; SMALL FIBER NEUROPATHY; UNSPECIFIED SIDE EFFECT;

EID: 84872044749     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefi nition and a grading system for clinical and research purposes. Neurology 2008; 70:1630-1635.
2. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9:807-819.
3. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011; 152(3 Suppl):S2-S15.
4. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009; 10:23-36.
5. Waetzig V, Czeloth K, Hidding U, et al. c-Jun N-terminal kinases (JNKs) mediate pro-infl ammatory actions of microglia. Glia 2005;50:235-2346.
6. Inoue K, Tsuda M. Microglia and neuropathic pain. Glia 2009; 57:1469-1479.
7. Miraucourt LS, Peirs C, Dallel R, Voisin DL. Glycine inhibitory dysfunction turns touch into pain through astrocyte-derived D-serine. Pain 2011; 152:1340-1348.
8. Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol 2011; 69:13-21.
9. Jaggi AS, Singh N. Mechanisms in cancerchemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012; 291:1-9.
10. Bennett GJ. Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist 2010; 15(Suppl 2):9-12.
11. Emery EC, Young GT, Berrocoso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in infl ammatory and neuropathic pain. Science 2011; 333:1462-1466.
12. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci 2010; 33:325-347.
13. Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Na1.7 mutations in idiopathic small fi ber neuropathy. Ann Neurol 2012; 71:26-39.
14. Ueda H. Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptormediated demyelination. Mol Pain 2008; 4:11.
15. Tigyi G. Lipids: LPA activates TRPV1--and it hurts. Nat Chem Biol 2012; 8:22-23.
16. Ueda H. Lysophosphatidic acid as the initiator of neuropathic pain. Biol Pharm Bull 2011; 34:1154-1158.
17. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992; 51:647-655.
18. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68:693-702.
19. Shaibani AI, Pope LE, Thisted R, Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a doubleblind, placebo-controlled, multicenter study. Pain Med 2012; 13:243-254.
20. Ziegler D, Hidvegi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33:839-841.
21. Shaibani A, Biton V, Rauck R, Koch B, Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur J Pain 2009; 13:458-463.
22. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fi bromyalgia in adults. Cochrane Database Syst Rev 2012; 2:CD009318.
23. Rao PP, Mohamed T. Current and emerging "at-site" pain medications: a review. J Pain Res 2011; 4:279-286.
24. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72:735-744.
25. Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress infl ammatory and neuropathic pain by targeting alpha3 glycine receptors. J Exp Med 2012; 209:1121-1134.
26. Steigerwald I, Muller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin 2012; 28:911-936.
27. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and effi cacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27:151-162.
28. Schroder W, Vry JD, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010; 14:814-821.
29. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)- phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-276.
30. Pierce DM, Shipstone E. Pharmacology update: Tapentadol for neuropathic pain. Am J Hosp Palliat Care 2012.
31. de Leon-Casasola O. New developments in the treatment algorithm for peripheral neuropathic pain. Pain Med 2011; 12(Suppl 3):S100-S108.
32. Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 2010; 23:602-610.
33. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113-e1188.
34. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107:490-502.
35. Wallace M, Pappagallo M. Qutenza(R): a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother 2011; 11:15-27.
36. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70:2305-2313.
37. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and metaanalysis of randomised controlled trials. PLoS One 2010; 5:e14433.
38. Saldana MT, Navarro A, Perez C, Masramon X, Rejas J. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int 2010; 30:1005-1015.
39. Navarro A, Saldana MT, Perez C, Torrades S, Rejas J. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol 2011; 11:7.
40. Mallison R, Tilke C, Brasser M, Pittrow D. Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions. MMW Fortschr Med 2007; 149:46.
41. Baron R, Freynhagen R, Tolle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010; 150:420-427.
42. Romano CL, Romano D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009; 10:185-191.
43. Pesonen A, Suojaranta-Ylinen R, Hammaren E, et al. Pregabalin has an opioid-sparing effect in elderly patients after cardiac surgery: a randomized placebocontrolled trial. Br J Anaesth 2011; 106:873-81.
44. Ittichaikulthol W, Virankabutra T, Kunopart M, Khamhom W, Putarawuthichai P, Rungphet S. Effects of pregabalin on post operative morphine consumption and pain after abdominal hysterectomy with/without salphingo-oophorectomy: a randomized, double-blind trial. J Med Assoc Thai 2009; 92:1318-23.
45. Ozgencil E, Yalcin S, Tuna H, Yorukoglu D, Kecik Y. Perioperative administration of gabapentin 1,200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study. Singapore Med J 2011; 52:883-9.
46. Kim JC, Choi YS, Kim KN, Shim JK, Lee JY, Kwak YL. Effective dose of peri-operative oral pregabalin as an adjunct to multimodal analgesic regimen in lumbar spinal fusion surgery. Spine (Phila Pa 1976) 2011; 36:428-33.
47. Zhang J, Ho KY, Wang Y. Effi cacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth 2011; 106:454-62.
48. Dauri M, Faria S, Gatti A, Celidonio L, Carpenedo R, Sabato AF. Gabapentin and pregabalin for the acute post-operative pain management. A systematicnarrative review of the recent clinical evidences. Curr Drug Targets 2009; 10:716-33.